drugset
drugset / Trial / NCT01751425

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

NCT01751425 ↗

Phase 1 Terminated 8 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies the side effects and best dose of ruxolitinib and to see how well it works in participants with chronic myeloid leukemia with minimal residual disease while on therapy with tyrosine kinase inhibitors. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2013-07-24
Primary completion
2019-09-24
Completion
2019-09-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule — Oral
Background Imatinib Small molecule — Oral
Background Nilotinib Small molecule — Oral
Background dasatinib anhydrous Small molecule — Oral

Indications

Philadelphia-positive myelogenous leukemia chronic myeloid leukemia